Skip to content
back

How will Annex 1 change fill/finish processes?

| 1 min read

Which implications will EU GMP Annex 1 have for sterile fill/finish processes? How will it change the way we work in the pharmaceutical industry? And which technologies are best suited?

 

Jürgen Metzger featured in Pharmaceutical Technology

 

On December 20, 2017, the European Commission published the long-awaited revision draft of EU GMP Annex 1. Even before its release, this document triggered many heated discussions, which have further intensified after publication. Topics include material classification for sterile transfers, detailed risk assessment procedures for processes and the associated environment, more operational qualification (OQ) testing, and laminar flow (LF) conditions for loading and preparing machines for production as well as reducing the overall risk from human intervention.

Our expert for barrier systems, Jürgen Metzger, discusses some of the most important issues in an in-depth article, which was recently published in Pharmaceutical Technology.

Jürgen Metzger is Barrier Systems & Process Specialist at Syntegon Technology. He started his career at Syntegon in 1999 in Crailsheim, Germany. Throughout his time in Germany, one of the main focus areas was isolator technology with aseptic filling machines and processes. Since April 2017, Metzger has been responsible for barrier systems technology in Minneapolis, MN.

 

Interested in our pharma solutions?

Interested in our pharma solutions?

Get in touch with us!
 
Worldwide contacts

Discover more about Syntegon

Thinking ahead together: the HTG Next Gen

Discover the HTG Next Gen, designed to minimize product loss and streamline the granulation process, addressing hidden costs with proven technology.

SPC: automating settle plate changes

Discover how our Settle Plate Changers (SPC) 2000 and 4000 can automate your compliance with Annex 1, enhancing both active and passive viable monitoring.

Tackling diabetes and obesity together

Discover seamless solutions for diabetes and obesity treatment with GLP-1 therapies. We support your needs from processing to assembly and inspection.